Carolina del Sur

Quiénes somos

  • 5 de abril de 2022
    Estudio de BMS-986253 en combinación con nivolumab o nivolumab más ipilimumab en cánceres avanzados.
  • 5 de abril de 2022
    Estudio de la plataforma TAPISTRY (Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You)
  • 5 de abril de 2022
    S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
  • 5 de abril de 2022
    An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.
  • 5 de abril de 2022
    Estudio de fase 3 de MRTX849 con cetuximab frente a quimioterapia en pacientes con cáncer colorrectal avanzado con mutación KRAS G12C (KRYSTAL-10)
  • 5 de abril de 2022
    Estudio de fase 1/2 de MRTX849 en pacientes con cáncer que presentan una mutación KRAS G12C KRYSTAL-1
  • 5 de abril de 2022
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
  • 5 de abril de 2022
    TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
  • 5 de abril de 2022
    A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
  • 5 de abril de 2022
    Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors